NEW YORK (GenomeWeb News) — Philips Life Sciences and Organon will perform biomarker studies that could benefit Philips’ imaging programs and Organon's drug-development efforts, the companies said yesterday.
Under the agreement, researchers from both companies will use Philips' labs and medical-imaging technologies to identify, validate, and pursue uses for novel biomarkers that Organon may use to develop drug programs for psychiatric and immune system disorders.
The companies said the research will be conducted at Philips' High Tech Campus in Eindhoven, the Netherlands.
Rick Harwig, Philips’ chief technology officer, said his company's imaging modalities are improving "to image the function and behavior of an anatomical feature, and not just its shape."
Harwig said working with Organon will help Philips "speed the evolution" of its imaging technology "into tools to image the body at the molecular level."